<DOC>
	<DOCNO>NCT00003991</DOCNO>
	<brief_summary>RATIONALE : Interleukin-2 may stimulate person 's white blood cell kill acute myeloid leukemia cell . Histamine dihydrochloride may prolong remission reduce risk relapse patient acute myeloid leukemia remission . PURPOSE : Randomized phase III trial determine effectiveness interleukin-2 plus histamine dihydrochloride treat patient acute myeloid leukemia remission follow previous therapy .</brief_summary>
	<brief_title>Interleukin-2 Plus Histamine Dihydrochloride Treating Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Compare efficacy interleukin-2 plus histamine dihydrochloride ( Maxamine ) v therapy prolong leukemia free survival patient acute myeloid leukemia first subsequent complete remission ( CR ) follow consolidation therapy . II . Compare relapse rate , overall survival , quality life patient population treat interleukin-2 plus Maxamine v therapy . III . Compare remission inversion rate patient subsequent CR treatment regimen vs therapy . OUTLINE : This randomize , open label , parallel , multicenter study . Patients stratify accord complete remission ( first v subsequent ) . Patients randomize one two treatment arm . Arm I : Following consolidation chemotherapy autologous stem cell transplantation , patient receive interleukin-2 subcutaneously follow histamine dihydrochloride subcutaneously 5-7 minute twice daily day 1-21 . Treatment repeat every 6 week 3 course every 9 week 7 course absence disease relapse unacceptable toxicity . Arm II : Patients receive therapy follow consolidation chemotherapy autologous stem cell transplantation . Quality life assess prior study , visit 6 , 7 , 10 , 11 , 16 , 17 , 22 . Patients follow relapse survival every 3 month 2.5 year . PROJECTED ACCRUAL : A total 360 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Histamine</mesh_term>
	<mesh_term>Histamine phosphate</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Cytologically confirm acute myeloid leukemia ( AML ) first complete remission ( CR ) subsequent CR Less 5 % blast normal bone marrow Less 3 month since last dose chemotherapy OR Less 6 month since achieve CR PATIENT CHARACTERISTICS : Age : 18 Performance status : WHO 01 OR Karnofsky 70100 % Life expectancy : Greater 3 month Hematopoietic : WBC least 1,500/mm3 Platelet count least 75,000/mm3 Hepatic : PTT normal Bilirubin great 2 time upper limit normal ( ULN ) SGOT SGPT great 2 time ULN Renal : Creatinine great 1.5 time ULN Cardiovascular : No class III IV heart disease No hypotension , severe hypertension , serious uncontrolled cardiac dysrhythmia ( e.g. , ventricular arrhythmia ) No acute myocardial infarction within past 12 month No active uncontrolled angina pectoris No symptomatic arteriosclerotic blood vessel disease Pulmonary : No history asthma within past 5 year Other : No active malignancy except localize basal squamous cell skin cancer carcinoma situ cervix HIV negative No prior active peptic esophageal ulcer disease No history hypersensitivity histamine histamine product , severe allergy Not pregnant nursing PRIOR CONCURRENT THERAPY : Biologic therapy : Prior autologous stem cell transplantation allow No prior allogeneic stem cell transplantation No concurrent immunomodulating agent Chemotherapy : See Disease Characteristics Prior induction consolidation therapy allow No concurrent chemotherapy Endocrine therapy : At least 24 hour since prior corticosteroid No concurrent steroids Radiotherapy : Not specify Surgery : Not specify Other : No concurrent alternative therapy ( e.g. , laetrile , Brudzinski 's treatment , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>adult acute myeloid leukemia remission</keyword>
</DOC>